pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

4,705 catalysts · 4,686 phase readout · 2,350 8k filing · 285 earnings · 253 pdufa · 172 phase 2 completion · 73 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 0 catalysts2026-07-23: 11 catalysts2026-07-24: 1 catalyst2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 0 catalysts2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: patent expiry×type: approval×type: filing×type: phase readout×clear all
type
  • phase readout4,686
  • 8k filing2,350
  • earnings285
  • pdufa253
  • phase 2 completion172
  • phase 1 completion73
phase 2 initiation
62
  • phase 1 initiation40
  • phase 1 2 completion35
  • phase 0 trial completion23
  • therapy area
    • Infectious Disease9
    • Ophthalmology5
    • Oncology2
    • Dermatology1
    • Pulmonology1

    Week of Apr 20, 2026

    4
    ›Apr 24, 2026patent expiry91d agoDaiichi Sankyo Co Ltd — laninamivir (Constraining Patent Expiry (Japan))laninamivir

    Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections

    full page →laninamivir →source: globaldata
    ›Apr 24, 2026patent expiry91d agoEisai Co Ltd — lenvatinib mesylate (Constraining Patent Expiry (US))lenvatinib mesylate

    Therapy area: Gastrointestinal, Infectious Disease, Oncology. Indication: Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing S

    full page →lenvatinib mesylate →source: globaldata
    ›Apr 25, 2026patent expiry90d agoStemline Therapeutics Inc — SL-901 (Constraining Patent Expiry (Japan))SL-901

    Therapy area: Oncology, Undisclosed. Indication: Lung Cancer, Solid Tumor, Unspecified Rare Disease

    full page →SL-901 →source: globaldata
    ›Apr 26, 2026patent expiry89d agoBlue Blood Biotech Corp — BB-101 (Constraining Patent Expiry (Japan))BB-101

    Therapy area: Dermatology. Indication: Diabetic Foot Ulcers

    full page →BB-101 →source: globaldata

    Week of Apr 27, 2026

    13
    ›Apr 27, 2026patent expiry88d agoBill & Melinda Gates Medical Research Institute — SB-692342 (Constraining Patent Expiry (Japan))SB-692342

    Therapy area: Infectious Disease. Indication: Pulmonary Tuberculosis

    full page →SB-692342 →source: globaldata
    ›Apr 28, 2026patent expiry

    Date TBD

    33
    ›TBDapprovalOZURDEX (DEXAMETHASONE) — FDA approvaldexamethasone LA

    Sponsor: ABBVIE. Form: IMPLANT. Route: INTRAVITREAL

    full page →dexamethasone LA →fda approvals ↗
    ›TBDapproval
    ← prev
    page 1 of 95
    next →
    87d ago
    GSK plc — dolutegravir sodium ODT (Constraining Patent Expiry (Japan))dolutegravir sodium

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →dolutegravir sodium →source: globaldata
    ›Apr 28, 2026patent expiry87d agoGSK plc — (abacavir sulfate + dolutegravir sodium+ lamivudine) ODT (Constraining Patent Expiry (Japan))(abacavir sulfate + dolutegravir sodium + lamivudine)

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →(abacavir sulfate + dolutegravir sodium + lamivudine) →source: globaldata
    ›Apr 28, 2026patent expiry87d agoGSK plc — cabotegravir sodium (Constraining Patent Expiry (US))cabotegravir sodium

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir sodium →source: globaldata
    ›Apr 28, 2026patent expiry87d agoViiV Healthcare UK Ltd — cabotegravir + rilpivirine LA (Constraining Patent Expiry (US))cabotegravir + rilpivirine LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir + rilpivirine LA →source: globaldata
    ›Apr 28, 2026patent expiry87d agoViiV Healthcare UK Ltd — cabotegravir LA (Constraining Patent Expiry (US))cabotegravir LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir LA →source: globaldata
    ›Apr 30, 2026patent expiry85d agoBasilea Pharmaceutica Ltd — isavuconazonium sulfate (Constraining Patent Expiry (US))isavuconazonium sulfate

    Therapy area: Infectious Disease. Indication: Aspergillosis, Candidiasis, Cryptococcal Meningitis, Cryptococcosis, Zygomycosis (Mucormycosis)

    full page →isavuconazonium sulfate →source: globaldata
    ›Apr 30, 2026filing85d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Wet (Neovascular / Exudative) Macular Degeneration

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026filing85d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Choroidal Neovascularization

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026filing85d agoSarepta Therapeutics Inc — golodirsen (NDA/BLA Filing (US))golodirsen

    Therapy area: Genetic Disorders. Indication: Duchenne Muscular Dystrophy

    full page →golodirsen →source: globaldata
    ›Apr 30, 2026filing85d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Retinal Vein Occlusion

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026filing85d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Diabetic Retinopathy

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026filing85d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Diabetic Macular Edema

    full page →ranibizumab biosimilar →source: globaldata
    TRILEPTAL (OXCARBAZEPINE) — FDA approvalOXCARBAZEPINE

    Sponsor: NOVARTIS. Form: TABLET. Route: ORAL

    full page →OXCARBAZEPINE →fda approvals ↗
    ›RECRUITINGphase readoutNCT06924671: GLA:D Back Canada - a Program for Chronic and Persistent Low Back Pain

    Sponsor: University of Alberta. Phase: . Conditions: Low Back Pain

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07542236: Hip and Ankle Mobility Rehabilitation for Soccer Players With Patellofemoral Pain

    Sponsor: Beijing Sport University. Phase: NA. Conditions: Patellofemoral Pain

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06941844: A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)Definium Therapeutics, Inc.

    Sponsor: Definium Therapeutics US, Inc.. Phase: PHASE3. Conditions: Major Depressive Disorder

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06466434: Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma

    Sponsor: M.D. Anderson Cancer Center. Phase: PHASE2. Conditions: Unresectable Melanoma

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06806709: Reducing Blood Culture Contamination With the Use of a Needle-less Blood Draw Device (The PIVO Trial)

    Sponsor: The University of Queensland. Phase: NA. Conditions: Blood Culture Contamination, Infection

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07178509: A Study of SCAD Using Stress Contrast EchocardiographyMayo Clinic

    Sponsor: Mayo Clinic. Phase: . Conditions: Spontaneous Coronary Artery Dissection

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07403409: Scapular Repeated Contractions Facilitation Versus Hold-relax Techniques in Patients With Adhesive Capsulitis

    Sponsor: Riphah International University. Phase: NA. Conditions: Adhesive Capsulitis of the Shoulder

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06721663: Multisensory Environment Stimulation Therapy on Postural Control in Cerebral Palsy

    Sponsor: October 6 University. Phase: NA. Conditions: Cerebral Palsy

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT06624787: Development Of A Rapid Diagnostic Test To Identify Crimean-Congo Haemorrhagic Fever At The Point-Of-Care

    Sponsor: Liverpool School of Tropical Medicine. Phase: NA. Conditions: Crimean-Congo Haemorrhagic Fever

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07527221: Safety and Tolerability of ZE74-0282 in Healthy VolunteersCerta Therapeutics Pty Ltd

    Sponsor: Eilean Therapeutics AU Pty Ltd. Phase: PHASE1. Conditions: Healthy Volunteers

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07329114: Healing Electroceutical Dressing for the Recovery of Open Wounds (HERO)

    Sponsor: Chandan Sen. Phase: NA. Conditions: Wound Heal, Wound Infection, Wound Healing Delayed, Wound of Skin, Infections

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT01778504: Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders

    Sponsor: National Institute of Mental Health (NIMH). Phase: . Conditions: Neuropsychiatric Disorder, Neurological Disorder, Neurodevelopmental Disorder, Sleep

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05103033: Systems Analysis and Improvement Approach to Optimize the Task-shared Mental Health Treatment Cascade (SAIA-MH)University of Washington

    Sponsor: University of Washington. Phase: NA. Conditions: Mental Health Disorder

    full page →ctgov ↗
    ›ENROLLING_BY_INVITATIONphase readoutNCT06906952: A Prospective Single-center Randomized Controlled Trial of Robotic Surgery With Transrectal Resection Specimens (NOSES-IV) and Traditional Assisted Robotic Surgery for the Treatment of High Rectal and Sigmoid Colon Cancer

    Sponsor: Nanchang University. Phase: NA. Conditions: Natural Orifice Specimen Extraction Surgery, Robotic Surgery, Short-term Outcomes

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07281547: Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and PainMayo Clinic

    Sponsor: Mayo Clinic. Phase: PHASE4. Conditions: Endometrial Carcinoma

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07442149: An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005ALUMIS INC.

    Sponsor: Alumis Inc. Phase: PHASE1. Conditions: Healthy Volunteer

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07418138: Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver Transplantation

    Sponsor: Hu Liangshuo. Phase: . Conditions: Liver Transplantation, Hepatocellular Carcinoma (HCC), Tyrosine Kinase Inhibitor, Survival Rate

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07362238: Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital

    Sponsor: Institute of Hematology & Blood Diseases Hospital, China. Phase: PHASE2. Conditions: Immune Thrombocytopenia, Treatment

    full page →ctgov ↗
    ›TERMINATEDphase readoutNCT04221438: Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node InvolvementArray BioPharma Inc

    Sponsor: ECOG-ACRIN Cancer Research Group. Phase: PHASE2. Conditions: Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT04461158: CCCR Lupus Patient Navigator Program

    Sponsor: Medical University of South Carolina. Phase: NA. Conditions: Systemic Lupus Erythematosus (SLE)

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07307248: To Evaluate Early (2-Week) vs. Standard (4-Week) Metal Stent Removal Following Endoscopic Ultrasound Guided WON Drainage

    Sponsor: Asian Institute of Gastroenterology, India. Phase: NA. Conditions: Walled Off Necrosis

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06877026: FibroScan-Reproducibility and Repeatability Study

    Sponsor: Echosens. Phase: NA. Conditions: Non-Alcoholic Fatty Liver Disease, Liver Disease; Alcohol-Related

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07418385: Voluntary HIV Screening in the General Population in France

    Sponsor: Université de Reims Champagne-Ardenne. Phase: . Conditions: Human Immunodeficiency Virus (HIV)

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT03078543: Ten Year Implant Survivorship of the ANTHEM™ PS Total Knee SystemSMITH & NEPHEW PLC

    Sponsor: Smith & Nephew, Inc.. Phase: . Conditions: Arthroplasty, Replacement, Knee

    full page →ctgov ↗
    ›ENROLLING_BY_INVITATIONphase readoutNCT07480343: 5-Year Postoperative Outcomes of Patients Who Completed the CREST Study

    Sponsor: Iantrek, Inc.. Phase: . Conditions: Open-angle Glaucoma (OAG)

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07550543: PEMF Therapy in Shoulder Tendinopathy

    Sponsor: Balnear and Rehabilitation Sanatorium Techirghiol. Phase: NA. Conditions: Shoulder Tendinopathy

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07298408: Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot StudyJazz Pharmaceuticals plc

    Sponsor: Florida A&M University. Phase: PHASE1. Conditions: Diabetic Peripheral Neuropathic Pain (DPN), Diabetic Neuropathies

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT07422025: Prognostic Value of Preoperative Frailty Assessment in Geriatric Lower Limb Orthopedic Surgery

    Sponsor: Benha University. Phase: . Conditions: Lower Limb Fracture

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07414576: AI-driven Total Parenteral Nutrition Platform

    Sponsor: Takeoff41, Inc.. Phase: NA. Conditions: Intestinal Failure

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05003817: Controlled Trial of High-risk Coronary Intervention With Percutaneous Left Ventricular UnloadingGuy's and St Thomas' NHS Foundation Trust

    Sponsor: Guy's and St Thomas' NHS Foundation Trust. Phase: PHASE3. Conditions: Ischemic Heart Disease, Coronary Artery Disease

    full page →ctgov ↗
    ›ENROLLING_BY_INVITATIONphase readoutNCT07450040: Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell LymphomaContinuity Biosciences LLC

    Sponsor: Eye & ENT Hospital of Fudan University. Phase: . Conditions: ORR, OS, PFS

    full page →ctgov ↗
    $ABBV253.30-1.09%
    $GSK50.76-0.04%
    $GSK50.76-0.04%
    $GSK50.76-0.04%
    $DFTX
    $SRPT15.82-2.41%
    $ALMS28.81-4.13%
    $SNN30.25+5.29%
    $JAZZ251.23+0.33%
    $NVS154.38+0.85%